Revision History

CVS Caremark will restore Eli Lilly's obesity drug Zepbound to its commercial formularies on October 1, 2026, reversing a July 2025 exclusion that affected an estimated 200,000 patients and triggered a class-action lawsuit. The reversal, announced alongside coverage of Lilly's new oral obesity pill Foundayo, raises fundamental questions about whether pharmacy benefit managers prioritize rebate revenue over patient outcomes — and whether patient backlash or behind-the-scenes contract renegotiation drove the decision.